Drug intelligence / Profile preview

GCC4001 + rituximab

Development stage: Unknown
Lead developer: Artiva Biotherapeutics
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

GCC4001 + rituximab is a combination therapy consisting of allogeneic, cord blood-derived naive natural killer (NK) cells (GCC4001, also known as AB-101) and the anti-CD20 monoclonal antibody rituximab. Developed by GC Cell (Yongin Cell Therapy Center), the therapy is designed to treat CD20-positive B-cell malignancies and certain autoimmune diseases. The mechanism of action leverages antibody-dependent cellular cytotoxicity (ADCC), where the NK cells recognize the Fc portion of rituximab bound to CD20-expressing target cells via their CD16a receptors, leading to enhanced cytotoxic killing of malignant or pathogenic B cells. It is currently being evaluated in Phase 1 clinical trials for relapsed or refractory B-cell non-Hodgkin lymphoma and is under investigation for refractory rheumatoid arthritis and other autoimmune conditions.

Brand names: Rituxan
Other names: AB-101 + rituximabNaive NK Cell + rituximab

Targets

CD20 (B-lymphocyte antigen CD20)FcγRIIIa (Low affinity immunoglobulin gamma Fc region receptor III-A)

Beyond the preview

Go deeper on GCC4001 + rituximab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GCC4001 + rituximab.

Explore the full profile